Bevacizumab, Everolimus (RAD001), and Lapatinib as Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer (GeparQuinto)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00567554 |
Recruitment Status :
Completed
First Posted : December 5, 2007
Last Update Posted : February 10, 2016
|
Sponsor:
German Breast Group
Collaborator:
AGO Study Group
Information provided by (Responsible Party):
German Breast Group
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Completed |
---|---|
Actual Primary Completion Date : | August 2011 |
Actual Study Completion Date : | October 2015 |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):